Clinical Trial

Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

Name: Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer — clinical trial record (NCT07662031)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is an open-label Phase 2 study to evaluate the safety and efficacy of Tovecimig combined with FOLFIRI in patients who have received one prior line of therapy for advanced or metastatic colorectal cancer (CRC).

Trial Details

NCT Number	NCT07662031
Lead Sponsor	Washington University School of Medicine Collaborators: Compass Therapeutics
Conditions	Colorectal Cancer, Metastatic Colorectal Cancer
Enrollment	25 participants
Start Date	2026-08-31
Primary Completion	2030-08-31 (estimated)
Study Completion	2032-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-23